---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-25-000088"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:54:42.687925+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech Q3 VYJUVEK revenue $97.8M; label expanded, EU/Japan launches

## Summary
- Q3 net product revenue $97.8M (vs $83.8M YoY); net income $79.4M ($2.74 basic EPS); cash $864.2M.
- FDA expanded VYJUVEK label to include DEB patients from birth and allow at-home application.
- VYJUVEK launched in Germany (Aug), France (Oct), and Japan (Oct); >615 US reimbursement approvals.
- FDA granted platform technology designation to HSV-1 vector used in KB801 and other programs.
- CF interim data (KB407) expected Q4; KB111 IND cleared for Hailey-Hailey disease; intratumoral KB707 enrollment paused.

## SEC filing metadata
- accession: 0001711279-25-000088
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000088/0001711279-25-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000088/krys-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-25-000088
- JSON: https://secwatch.observer/filing/0001711279-25-000088.json
- Plain text: https://secwatch.observer/filing/0001711279-25-000088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.